Clinical trial
A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria…
NCT03905694 · Alnylam Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03905694 |
|---|---|
| Title | A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 |
| Official title | ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1 |
| Acronym | ILLUMINATE-B |
| Lead sponsor | Alnylam Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1) |
| Intervention type | Drug |
| Interventions | Lumasiran |
| Enrollment | 18 |
| Start date | Apr 22, 2019 |
| Primary completion | Jun 29, 2020 |
| Completion | Jul 26, 2024 |
| First posted | Apr 5, 2019 |
| Last update posted | Feb 14, 2025 |
| Countries | France, Germany, Israel, United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: